首页> 美国卫生研究院文献>Journal of Enzyme Inhibition and Medicinal Chemistry >Synthesis molecular modelling and anticancer evaluation of new pyrrolo12-bpyridazine and pyrrolo21-aphthalazine derivatives
【2h】

Synthesis molecular modelling and anticancer evaluation of new pyrrolo12-bpyridazine and pyrrolo21-aphthalazine derivatives

机译:新型吡咯并12-b哒嗪和吡咯并21-a酞嗪衍生物的合成分子建模和抗癌性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two new series of heterocyclic derivatives with potential anticancer activity, in which a pyrrolo[1,2-b]pyridazine or a pyrrolo[2,1-a]phthalazine moiety was introduced in place of the 3′-hydroxy-4′-methoxyphenyl ring of phenstatin have been synthesised and their structure-activity relationship (SAR) was studied. Fourteen of the new compounds were evaluated for their in vitro cytotoxic activity by National Cancer Institute (NCI) against 60 human tumour cell lines panel. The best five compounds in terms of in vitro growth inhibition were screened in the second stage five dose-response studies, three of them showing a very good antiproliferative activity with GI50<100 nM on several cell lines including colon, ovarian, renal, prostate, brain and breast cancer, melanoma and leukemia. Docking experiments on the biologically active compounds showed a good compatibility with the colchicine binding site of tubulin.
机译:具有潜在抗癌活性的两个新的杂环衍生物系列,其中引入了吡咯并[1,2-b]哒嗪或吡咯并[2,1-a]酞嗪部分取代了3'-羟基-4'-甲氧基苯基合成了吩他汀环,并研究了它们的构效关系。美国国家癌症研究所(NCI)评估了14种新化合物对60种人类肿瘤细胞系的体外细胞毒性活性。在第二阶段的五个剂量反应研究中,筛选出了体外生长抑制效果最好的五种化合物,其中三种显示出GI50 <100,nM对多种细胞系(包括结肠,卵巢,肾,前列腺,脑和乳腺癌,黑色素瘤和白血病。对生物活性化合物的对接实验显示与微管蛋白的秋水仙碱结合位点具有良好的相容性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号